Quick Answer
Monopar Therapeutics reported Shares Outstanding of 6.69 million shares for fiscal year 2025.
Monopar Therapeutics Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 6.69M | +9.7% |
| 2024 | 6.10M | +104.7% |
| 2023 | 2.98M | -77.0% |
| 2022 | 12.95M | +2.8% |
| 2021 | 12.60M | +10.0% |
| 2020 | 11.45M | +8.2% |
| 2019 | 10.59M | +14.0% |
| 2018 | 9.29M | +0.0% |
| 2017 | 9.29M | — |
| 2016 | 0 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 6.66M | +89.0% | +8.7% |
| June 30, 2025 | 6.13M | -65.2% | +0.2% |
| March 31, 2025 | 6.12M | -65.0% | +0.2% |
| December 31, 2024 | 6.10M | +104.7% | +73.1% |
| September 30, 2024 | 3.53M | -75.2% | -80.0% |
| June 30, 2024 | 17.60M | +26.6% | +0.7% |
| March 31, 2024 | 17.48M | +32.2% | +486.5% |
| December 31, 2023 | 2.98M | -77.0% | -79.0% |
- Monopar Therapeutics showed an increase of +9.7% in Shares Outstanding compared to the prior fiscal year.
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: